DarioHealth Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DRIO research report →
Range $6 – $6
Price Chart
About the company
DarioHealth Corp. is a digital therapeutics enterprise operating across the United States, Canada, the European Union, Australia, and New Zealand. The company delivers a suite of digital health solutions, including its 'Dario' metabolic programs designed to address conditions like diabetes, hypertension, and weight management.
- CEO
- Erez Raphael
- IPO
- 2016
- Employees
- 163
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on DRIO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $14.90M
- P/E
- 8.80
- PEG
- -0.15
- P/S
- 0.70
- P/B
- 0.22
- EV/EBITDA
- -0.69
- Div Yield
- 0.00%
- Gross Margin
- 55.90%
- Op Margin
- -317.39%
- Net Margin
- 286.38%
- ROE
- 95.08%
- ROIC
- -64.51%
Latest fiscal year · YoY change
- Revenue
- $22.36M-17.3%
- Gross Profit
- $12.66M-4.5%
- Op Income
- $-36,655,000
- Net Income
- $-41,714,000+2.4%
- EPS
- $-0.81-9.5%
- OCF Growth
- +32.7%
- FCF Growth
- +32.6%
- 52W High
- $14.49
- 52W Low
- $1.09
- 50D MA
- $4.46
- 200D MA
- $7.05
- Beta
- 1.18
- RSI (14)
- 24
- Avg Volume
- 48.52K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
DarioHealth posted modest 6% revenue growth, improved losses and margins year over year, and said its multi-condition, channel-led model is setting up a larger revenue ramp into 2027 and 2028.· November 12, 2026
- Revenue was $5.3 million, up 6% year over year; gross margin was 59% versus 60% a year ago.
- Operating expenses fell 10% year over year to $11.2 million, helping operating loss improve to $8 million and net loss to $8.8 million.
- Contracted and late-stage ARR ended at approximately $13.1 million, with management saying conversion should ramp gradually into 2027 and 2028.
- Channel partners drove about 75% of new accounts, and management said channel distribution should remain the primary growth engine into 2027 and beyond.
- DarioIQ was described as now producing measured engagement benefits, and management said it could add up to approximately 14% to engagement-based ARR from existing customers.
Revenue for the third quarter of 2026 was $5.3 million, up 6% from $5 million in Q3 2025 and up 3% from $5.2 million in Q2 2026. Gross margin was 59%, compared with 60% in the prior-year quarter and 62% in the prior quarter. Operating expenses were $11.2 million, down 10% year over year; operating loss improved 15% year over year to $8 million; net loss improved to $8.8 million from $10.5 million a year ago; and non-GAAP operating loss narrowed to $5.3 million from $6 million. As of September 30, 2026, cash, cash equivalents and short-term deposits were $31.2 million. Management said it expects revenue to accelerate at the end of 2026 into 2027, driven by conversion of contracted and late-stage ARR, and later said the $13.1 million in contracted and late-stage ARR would convert into 2027 and some into 2028. They also said they believe the company is on track to reach breakeven in 2028.
Erez Raphael framed the quarter as evidence that Dario’s strategy is compounding across four drivers: account depth, distribution efficiency, AI leverage and value chain participation. He emphasized that more than 80% of contracted and late-stage recurring revenue is now multi-condition and said the market is shifting toward consumer choice plus payer-funded care, where Dario believes it is positioned. His tone was confident and strategic, repeatedly pointing to 2027 revenue acceleration and the company’s role at the intersection of consumer and payer models.
Chen Franco said the business is becoming more efficient, highlighting $5.3 million of revenue, 59% gross margin, $11.2 million of operating expenses, and a $31.2 million cash balance as of September 30, 2026. He noted that non-GAAP B2B2C gross margin remained about 80% for the 11th consecutive quarter and that AI, lower headcount, lower stock-based compensation and post-merger integration savings are helping reduce costs. He also said the model should show operating leverage as signed accounts activate and existing customers add conditions, with each additional dollar of B2B2C revenue expected to carry high gross margin and help narrow operating loss and cash burn.
Analysts focused on the timing and size of conversion from the approximately $13.1 million of contracted and late-stage ARR, especially the ASO portion. Management said most of that ARR should convert gradually in 2027 and 2028, that more than half is not ASO, and that the Q4 2026 step-up should be limited, with the Jersey win not yet included in the total because it is also ASO; Erez also said consensus for 2027 looks aligned. Questions also centered on GLP-1 coverage trends, where Lara said the market is splitting between traditional PBM coverage, carve-outs with subsidies, and hybrid/direct-to-consumer approaches, and that about 80% of commercial conversations currently involve carve-out-style discussions. Analysts also asked about women’s health, sleep and channel-partner ramp timing; management said those offerings are early but should start contributing in 2027, while channel relationships are already in place and should scale faster because roughly 75% of new accounts come through partners.
The call showed real year-over-year revenue growth, margin stability, and a meaningful reduction in operating losses, while management argued that the business is still early in a larger revenue conversion cycle. Dario also pointed to strong channel momentum, a growing multi-condition footprint, and measurable early benefits from DarioIQ, plus a potential 2027-2028 ramp from contracted ARR and new offerings like GLP-1 support, women’s health and sleep.
Revenue remains small at $5.3 million, gross margin slipped to 59% from 62% sequentially, and management acknowledged that a large part of the $13.1 million in contracted ARR is ASO-related and will convert slowly. The company is still loss-making, and management’s optimism about 2027 and breakeven in 2028 depends on converting signed accounts, executing channel launches and navigating a changing GLP-1 reimbursement environment that management said is still in flux.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 66.7%
- Shares Outstanding
- 11.29M
- Float Shares
- 7.53M
of shares held by institutions
22 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Nantahala Capital Management, LLC | 978.34K | ▲ 367.65K |
| Citadel Advisors LLC | 447.62K | ▲ 423.33K |
| Vanguard Group Inc | 99.30K | ▲ 68.90K |
| Vanguard Capital Management LLC | 77.34K | ▲ 11.67K |
| Geode Capital Management, LLC | 67.53K | ▲ 9.49K |
| Vanguard Fiduciary Trust Co | 44.44K | ▲ 7.05K |
| Blackrock, Inc. | 38.83K | ▲ 1.04K |
| Commonwealth Equity Services, LLC | 24.00K | ▲ 24.00K |
| Northern Trust Corp | 13.24K | 0 |
| Ubs Group AG | 3.81K | ▲ 3.67K |
| Vanguard Global Advisers, LLC | 3.32K | 0 |
| Morgan Stanley | 3.00K | 0 |
Held by 11 ETFs
Biggest fund positions in DRIO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 24, 26 | PALUMBO JOHN R | other | 62,000 |
| Sep 24, 26 | STERN ADAM K | other | 28,000 |
| Sep 18, 25 | STERN ADAM K | other | 8,435 |
| Sep 18, 25 | STERN ADAM K | other | 11,760 |
| Sep 18, 25 | STERN ADAM K | other | 250 |
| Sep 18, 25 | STERN ADAM K | other | 100 |
| Sep 24, 26 | MCGRATH DENNIS M | other | 61,000 |
| Sep 24, 26 | Shaked Yoav | other | 54,000 |
| Aug 12, 24 | Shaked Yoav | other | 772 |
| Aug 12, 24 | Shaked Yoav | other | 40 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our DRIO coverage
Recent articles, reports, and earnings notes.
No research on DRIO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DRIO report →Dario CEO Erez Raphael to Lead Panel Discussion at U.S. Bancorp | BTIG Tech-Enabled Healthcare Forum
prnewswire.com · Nov 20
Dario and WebMD Health Services Announce Strategic Partnership to Deliver Dario's Multi-Condition Platform to Millions of Covered Lives
prnewswire.com · Nov 19
Dario Secures Second Women's Health Contract in Just Weeks with The Minnesota Star Tribune
prnewswire.com · Nov 18
Dario Presents New Research at ISPOR Europe 2026 Validating a Biometric-Driven Approach to Estimating Healthcare Cost Savings and ROI - Consistent with Published Benchmarks and Without Waiting for Cla
gurufocus.com · Nov 16
Dario Presents New Research at ISPOR Europe 2026 Validating a Biometric-Driven Approach to Estimating Healthcare Cost Savings and ROI - Consistent with Published Benchmarks and Without Waiting for Claims Data
prnewswire.com · Nov 16
DarioHealth Corp. (DRIO) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 12
DarioHealth Corp. (DRIO) Reports Q3 Loss, Tops Revenue Estimates
zacks.com · Nov 12
DarioHealth Reports Third Quarter 2026 Financial Results: Year-over-Year Revenue Growth and Operating Expense Reduction
prnewswire.com · Nov 12
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.